GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

barzolvolimab   Click here for help

GtoPdb Ligand ID: 11607

Synonyms: CDX-0159
Compound class: Antibody
Comment: Barzolvolimab (CDX-0159) is a clinical stage humanized anti-KIT IgG1 monoclonal antibody that was developed by Celldex Therapeutics (as claimed in their patent US10781267B2) [1]. CDX-0159 is a variant of CDX-0158 (a.k.a. KTN0158 [2]) that was re-engineered to improve its safety profile and increase its serum half-life. CDX-0158 was originally designed for potential to treat GIST and other KIT-dependent tumours. This original version of the antibody inhibits mutant and wild type KIT phosphorylation, reduces mast cell degranulation and mast cell numbers, and shrinks tumours in a preclinical canine model of spontaneous mast cell tumour development [2].
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11842 barzolvolimab
Synonyms Click here for help
CDX-0159
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1205
Other databases
GtoPdb PubChem SID 442878641
Search PubMed clinical trials barzolvolimab
Search PubMed titles barzolvolimab
Search PubMed titles/abstracts barzolvolimab